Estrogen receptor negative (ER-)/progesterone receptor negative (PR-)/human epidermal receptor growth factor 2 negative (HER2-), or triple-negative BC (TNBC) account for approximately 15% of BC. This evidence concerns the gene ERBB2 and breast cancer.